These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31565761)

  • 41. HARMONIZING HEALTH TECHNOLOGY ASSESSMENT PRACTICES IN UNIVERSITY HOSPITALS: TO WHAT EXTENT IS THE MINI-HTA MODEL SUITABLE IN THE FRENCH CONTEXT?
    Martelli N; Devaux C; van den Brink H; Billaux M; Pineau J; Prognon P; Borget I
    Int J Technol Assess Health Care; 2017 Jan; 33(2):307-314. PubMed ID: 28580892
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mental health economics: insights from Brazil.
    Cruz L; Lima AF; Graeff-Martins A; Maia CR; Ziegelmann P; Miguel S; Fleck M; Polanczyk C
    J Ment Health; 2013 Apr; 22(2):111-21. PubMed ID: 23574503
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treacle and Smallpox: Two Tests for Multicriteria Decision Analysis Models in Health Technology Assessment.
    Morton A
    Value Health; 2017 Mar; 20(3):512-515. PubMed ID: 28292498
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HTA and its legal issues: a framework for identifying legal issues in health technology assessment.
    Widrig D; Tag B
    Int J Technol Assess Health Care; 2014 Dec; 30(6):587-94. PubMed ID: 25816824
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Changing roles of decision analysis and cost-effectiveness analyses in medicine and radiology.
    McNeil BJ
    Eur Radiol; 2000; 10 Suppl 3():S340-3. PubMed ID: 11001440
    [No Abstract]   [Full Text] [Related]  

  • 46. When Future Change Matters: Modeling Future Price and Diffusion in Health Technology Assessments of Medical Devices.
    Grimm SE; Dixon S; Stevens JW
    Value Health; 2016; 19(6):720-726. PubMed ID: 27712696
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HEALTH TECHNOLOGY ASSESSMENT METHODS GUIDELINES FOR MEDICAL DEVICES: HOW CAN WE ADDRESS THE GAPS? THE INTERNATIONAL FEDERATION OF MEDICAL AND BIOLOGICAL ENGINEERING PERSPECTIVE.
    Polisena J; Castaldo R; Ciani O; Federici C; Borsci S; Ritrovato M; Clark D; Pecchia L
    Int J Technol Assess Health Care; 2018 Jan; 34(3):276-289. PubMed ID: 29909792
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Benefit assessments for medical technology devices: Strategic challenges for clinical research].
    Schönermark MP
    HNO; 2015 Aug; 63(8):586-8. PubMed ID: 26204843
    [No Abstract]   [Full Text] [Related]  

  • 49. The Impact of Decision Makers' Constraints on the Outcome of Value of Information Analysis.
    Koffijberg H; Knies S; Janssen MP
    Value Health; 2018 Feb; 21(2):203-209. PubMed ID: 29477402
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of Culture, Values, and Politics in the Implementation of Health Technology Assessment in India: A Commentary.
    Swami S; Srivastava T
    Value Health; 2020 Jan; 23(1):39-42. PubMed ID: 31952672
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA).
    Wahlster P; Goetghebeur M; Kriza C; Niederländer C; Kolominsky-Rabas P;
    BMC Health Serv Res; 2015 Jul; 15():262. PubMed ID: 26152122
    [TBL] [Abstract][Full Text] [Related]  

  • 52. To HTA or Not to HTA: Identifying the Factors Influencing the Rapid Review Outcome in Ireland.
    Murphy A; Redmond S
    Value Health; 2019 Apr; 22(4):385-390. PubMed ID: 30975388
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Representing uncertainty: the role of cost-effectiveness acceptability curves.
    Fenwick E; Claxton K; Sculpher M
    Health Econ; 2001 Dec; 10(8):779-87. PubMed ID: 11747057
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Decision Making and Priority Setting: The Evolving Path Towards Universal Health Coverage.
    Paolucci F; Redekop K; Fouda A; Fiorentini G
    Appl Health Econ Health Policy; 2017 Dec; 15(6):697-706. PubMed ID: 28871512
    [TBL] [Abstract][Full Text] [Related]  

  • 55. INTRODUCTION OF HEALTH TECHNOLOGY ASSESSMENT FOR MEDICINES IN SLOVAKIA.
    Tesar T; Hloska A; Wawruch M; Lehocka L; Snopkova M; Masarykova L
    Int J Technol Assess Health Care; 2017 Jan; 33(3):345-349. PubMed ID: 28434416
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Organisational impact: Definition and assessment methods for medical devices.
    Roussel C; Carbonneil C; Audry A;
    Therapie; 2016 Feb; 71(1):69-96. PubMed ID: 27080633
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An Evidence Framework for Off-Patent Pharmaceutical Review for Health Technology Assessment in Emerging Markets.
    Brixner D; Kaló Z; Maniadakis N; Kim K; Wijaya K
    Value Health Reg Issues; 2018 Sep; 16():9-13. PubMed ID: 29605800
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adapting health technology assessment for drugs, medical devices, and health programs: Methodological considerations from the Indian experience.
    Prinja S; Jyani G; Gupta N; Rajsekar K
    Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):859-868. PubMed ID: 33882762
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prioritizing Healthcare Interventions: A Comparison of Multicriteria Decision Analysis and Cost-Effectiveness Analysis.
    Wilson R; Chua J; Pryymachenko Y; Pathak A; Sharma S; Abbott JH
    Value Health; 2022 Feb; 25(2):268-275. PubMed ID: 35094800
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
    Allen N; Walker SR; Liberti L; Salek S
    Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.